Just as effective as the high dose, low-dose apixaban prevents long-term recurrent venous thromboembolism in patients with ...

The Phase III API-CAT trial found that extended anticoagulant therapy with reduced-dose Eliquis (apixaban) was noninferior to ...

In patients with active cancer and venous thromboembolism, whether extended treatment with a reduced dose of an oral ... deep-vein thrombosis or pulmonary embolism who had completed at least ...

Purpose The pharmacology, pharmacokinetics, efficacy, and safety of apixaban are reviewed ... and has been administered in a twice-daily dosing regimen in clinical trials without the need for ...

A study shows reduced-dose apixaban effectively prevents recurrent blood clots in cancer patients, lowering bleeding risks ...

On top of noninferior efficacy, the trial showed patients had less bleeding with 2.5 mg vs 5.0 mg twice daily over 12 months.

For extended anticoagulation after venous thromboembolism (VTE) in patients with active cancer, a lower dose of apixaban ...

The aim of the API-CAT trial was to assess whether the lower dose of apixaban was comparable to the full dose in preventing VTE recurrence in patients with active cancer who had completed at least ...

Results show noninferiority to a full dose in preventing a recurrence of blood clots and an advantage when it comes to ...

Patients with active cancer who developed a blood clot, or venous thromboembolism (VTE), and were treated with blood-thinning medication for at least six months, followed by an additional 12 months of ...

You can stop taking Eliquis without tapering your dosage first. However, if you stop Eliquis sooner than your doctor recommends, you may have an increased risk of blood clots. Eliquis has a boxed ...